Innovimmune

Innovating Immunity. Drug Discovery Biotech company developing novel oral immunotherapies for Cancer & Autoimmune Diseases.

[Innovimmune @Innovimmune]

Join us at our poster presentation of our preclinical findings of INV-71 ROR gamma agonists for breast cancer #ESMO22 #breastcancer #immunotherapy https://t.co/Ogtcnd0stD

[JAMA Oncology @JAMAOnc]

Updated 5-year results of the Unicancer PRODIGE 24/CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for pts w #pancreaticcancer. https://t.co/rCFntho0f1 #GICSM

[Innovimmune @Innovimmune]

@wiengesundheit https://t.co/hhXVplEChz

[Innovimmune @Innovimmune]

We are pleased to announce the presentation of INV-71 ROR gamma modulators in preclinical breast cancer at #ESMO22 Paris by presenting author Prof. Sebesta, Chair, Vienna Cancer Center. https://t.co/uJQS1tnBGl
@cityofhope @uscnorris @Innovimmune @wiengesundheit @myESMO

[Innovimmune @Innovimmune]

Explore our first-in-class, best-in-class oral therapies for Cancer and Autoimmune, Inflammatory & Rare diseases. Let's meet at BIO 2022 in San Diego.
https://t.co/IP9GWtGKLU
#bio2022 #cancer #cancertreatment #autoimmune #raredisease #inflammation

[Innovimmune @Innovimmune]

Thanks to all colleagues for the enthusiasm and engaging brainstorming session on our Oral INV-88 MIF inhibitors #AACR22 @AACR @ASCO @myESMO @cityofhope @Innovimmune #KlinikDonaustadt

[Innovimmune @Innovimmune]

@bradloncar Exactly, but also by lack of "diversity". It is imperative to focus on targets of the other immune compartments as well BEYOND B, need more Rx approaches against NK, MΦ, T, MDSC.
@matthewherper @bradloncar @AGKootenay @PharmaceuticBen @JohnCendpts

[Matthew Herper @matthewherper]

Natural killer cells, primed with an antibody, induce remissions in patients with advanced lymphoma

By @adamfeuerstein #AACR22.

https://t.co/VtfzlvNAC9

[Innovimmune @Innovimmune]

A critical tumorigenic cytokine Macrophage Migration Inhibitory Factor (MIF), a difficult intractable drug target, now druggable with oral small molecules! Innovimmune presents INV-88 #AACR22 @AACR @cityofhope @FollowStevens #KlinikDonaustadt @wiengesundheit @ESMO @ASCO

[Innovimmune @Innovimmune]

@matthewherper @adamfeuerstein @damiangarde Me and my colleagues in the drug development world have been great followers (before Social Media!) of you for 25 years. Congratulations for your outstanding scientific journalism. @Innovimmune

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in harnessing natural killer cells for cancer immunotherapy, for which promising early-stage results have been reported at #AACR22, here's a comprehensive recent review https://t.co/VS2svJ0nxY
Readcube version https://t.co/zbHifjuEQv

[Gʀᴇɢᴏʀʏ Rɪᴇʟʏ @RielyMD]

Great talk exploring associations between genomics of lung cancer and ethnicity by Matt Meyerson featuring work of @CarrotJian (https://t.co/BGGRnSLGBd) #AACR22

[Wiener Gesundheitsverbund @wiengesundheit]

Wie funktioniert die #Chemotherapie & was passiert bei der Immuntherapie? Christian Sebesta, Vorstand der 2. Med. der #KlinikDonaustadt, erklärt was bei diesen Therapieformen mit dem Körper passiert. Patient Walter Vock gibt Einblick in seinen Behandlungsverlauf.

[Innovimmune @Innovimmune]

Innovimmune announces presentation of it’s novel cancer immunotherapy program: Oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors, at the 2022 AACR Meeting in New Orleans.
Learn more. https://t.co/ocQJDQVoTL
#AACR22 #immunotherapy #oncology #cancer @AACR

[Jacob Plieth @JacobPlieth]

A few early themes from #AACR22, via @evaluatevantage https://t.co/gc9zPU0gpX

[Innovimmune @Innovimmune]

Meet us during #BIODigital week, June 8-12, for a virtual gathering of the global biotech industry! https://t.co/QsQUvHThAp

[Innovimmune @Innovimmune]

#PartneringAgainstCovid19 We are seeking out-licensing partners for the fast-tracked development of our proprietary INV-88 oral macrophage migration inhibitory factor inhibitors https://t.co/QtMaMB5QXr as a novel anti-cytokine-storm targeted therapy for ARDS in COVID-19.

[Innovimmune @Innovimmune]

#PartneringAgainstCovid19

[Innovimmune @Innovimmune]

Blocking Macrophage Migration Inhibitory Factor a more elegant approach vs targeting proinflammatory IL-6, IL-1b in ameliorating cytokine release syndrome in COVID-19? https://t.co/8jpWpVQUvK #MIF #INV-88 #COVID-19

[Innovimmune @Innovimmune]

Blocking Macrophage Migration Inhibitory Factor a more elegant approach vs targeting proinflammatory IL-6, IL-1b in ameliorating cytokine release syndrome in COVID-19? https://t.co/8jpWpVQUvK #MIF #INV-88 #COVID-19

[Foundation for Airway Health @AirwayFdn]

MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) https://t.co/L8c0sX5U1e